Pasireotide LAR is a safe and effective treatment of acromegaly: interim results from a randomized, multicenter, pharmacokinetic/pharmacodynamic, a Phase I study

Petersenn, S.; Bollerslev, J.; Arafat, A.; Glusman, J.E.; Serri, O.; Hu, M.; Schopohl, J.; Maiter, Dominique; Jung, C.; Strasburger, C.; Beckers, A.

Pasireotide LAR is a safe and effective treatment of acromegaly: interim results from a randomized, multicenter, pharmacokinetic/pharmacodynamic, a Phase I study

Petersenn, S.

;

Bollerslev, J.

;

Arafat, A.

;

Glusman, J.E.

;

Beckers, A.

;et.al.

(2008) ENDO 2008: The Endocrine Society 90th Annual Meeting — Location: (United States) San Francisco, CA (15.June.2008)

Files

No attached file found for this publication.

Details

Authors

Petersenn, S.
Author
Bollerslev, J.
Author
Arafat, A.
Author
Glusman, J.E.
Author
Maiter, DominiqueUCLouvain
Author
Beckers, A.
Author

Affiliations

Citations

APA
Chicago
FWB

Petersenn, S., Bollerslev, J., Arafat, A., Glusman, J. E., Serri, O., Hu, M., Schopohl, J., Maiter, D., Jung, C., Strasburger, C., & Beckers, A. (2008). Pasireotide LAR is a safe and effective treatment of acromegaly: interim results from a randomized, multicenter, pharmacokinetic/pharmacodynamic, a Phase I study. ENDO 2008: The Endocrine Society 90th Annual Meeting, (United States) San Francisco, CA. https://hdl.handle.net/2078.5/203437